Randox, Crumlin, UK, has launched the Qnostics SARS-CoV-2 Medium Q control, designed to ensure the accuracy and reliability of molecular assays used in diagnostic testing for covid-19.
The control contains the whole SARS CoV-2 genome and is compatible with commercial and in-house assays targeting the consensus sequences accepted by the US Centers for Disease Control and Prevention and the World Health Organization.
Full process control enables the user to monitor the performance of the entire testing process from extraction and amplification through detection. The control is supplied in a liquid frozen format, so no additional preparation or handling is required. Complementary negative controls are available, providing a complete testing package.
For more information, visit Randox.
